Category: Letter From the Editor
Letter From the Editor: Examining the Use of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
Last month’s issue of the journal Gastroenterology & Hepatology delved into the use of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with inflammatory bowel disease (IBD). […]
Letter From the Editor: Exploring Glucagon-Like Peptide-1 Receptor Agonist Use in Inflammatory Bowel Disease Patients
The use of glucagon-like peptide-1 (GLP-1) receptor agonists is soaring in popularity to the point that these drugs are becoming household names. This month’s issue of […]
Letter From the Editor: Examining Hyperbaric Oxygen Therapy for Inflammatory Bowel Disease Patients
Is there a role for using hyperbaric oxygen therapy to treat patients who have inflammatory bowel disease (IBD)? This month’s issue of Gastroenterology & Hepatology includes […]
Letter From the Editor: Exploring Alcohol Use Disorder and Alcohol-Associated Liver Disease
Alcohol-associated liver disease (ALD) is one of the most common causes of liver-related morbidity and death globally. Consuming alcohol elevates the risk of ALD development and […]
Letter from the Editor: Remote Monitoring of Inflammatory Bowel Disease
Remote Monitoring of Inflammatory Bowel Disease Does remote monitoring represent the future of inflammatory bowel disease (IBD) patient management in the United States? One of the […]
Letter From the Editor: Diagnosing and Treating Noncardiac Chest Pain
Noncardiac chest pain is a common condition that can be difficult to diagnose and manage. One of the feature articles in this month’s issue of Gastroenterology […]
Letter From the Editor: Examining Pharmacoequity in Older Inflammatory Bowel Disease Patients
How can pharmacoequity be achieved in older patients with inflammatory bowel disease (IBD)? This question is explored in the Advances in IBD column in this month’s […]
Letter From the Editor: Exploring the Use of Biosimilars to Treat Patients With Inflammatory Bowel Disease
How and when should biosimilars be used to treat patients with inflammatory bowel disease (IBD)? With more than 10 infliximab and adalimumab biosimilars now available in […]
Letter From the Editor: Examining Ergonomic Issues in Endoscopy
How can ergonomic wellness be best supported in the field of endoscopy in 2024? This question is explored in the Advances in Endoscopy column in this […]
Letter From the Editor: Exploring Diets Beyond the Low-FODMAP Diet to Treat Patients With IBS
For the management of patients with irritable bowel syndrome (IBS), most dietary guidelines recommend first trying so-called traditional IBS dietary advice and then a diet low […]
Letter From the Editor: Exploring Cardiovascular Comorbidities and Inflammatory Bowel Disease
Heart disease has been the number one cause of death in the United States for more than a century, according to the Centers for Disease Control […]
Letter From the Editor: Applications of Artificial Intelligence in Esophageal Diseases
Can artificial intelligence (AI) improve our management of esophageal diseases? This month’s issue of Gastroenterology & Hepatology explores the potential use of AI in patients with […]
Letter From the Editor: Exploring Vaccination in Patients With Inflammatory Bowel Disease
Vaccination has become a polarizing issue in the United States, as Dr Francis A. Farraye notes in this month’s issue of Gastroenterology & Hepatology. Two of […]
Letter From the Editor: Marking Our Twentieth Year of Covering Gastroenterology and Hepatology
The journal Gastroenterology & Hepatology marks the beginning of its twentieth year of publication with a wide variety of informative and clinically relevant articles. Among the […]
Letter From the Editor: Examining Janus Kinase Inhibitors for the Treatment of Inflammatory Bowel Disease
How different are drugs in the same class? A review article in this month’s issue of Gastroenterology & Hepatology explores this question in a comprehensive overview […]
Letter From the Editor: Spotlight on Hepatology
In anticipation of the upcoming Liver Meeting, being held in Boston, Massachusetts in November, this month’s issue of Gastroenterology & Hepatology shines a spotlight on hepatology. […]
Letter From the Editor: Managing Older Patients Who Have Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) was often considered a disease of the young in the past. However, with a recent epidemiologic shift, older adults now comprise the […]
Letter From the Editor: Shifting Our Focus From NASH to MASH
This month’s issue of Gastroenterology & Hepatology features our newly titled MASH in Focus column, formerly NASH in Focus. This name change reflects the new liver […]
Letter From the Editor: Small Molecule and Biologic Therapies for Ulcerative Colitis
Currently, there are a number of different small molecule and biologic therapies approved by the US Food and Drug Administration (FDA) for the treatment of patients […]
Nonalcoholic Steatohepatitis Drug Development
Worldwide, the most common cause of chronic liver disease is now nonalcoholic fatty liver disease, which affects a quarter of the population. This disease is a […]